McLean Hospital, 115 Mill Street, AB3S, Belmont, MA, 02478, USA.
Department of Psychiatry, Harvard Medical School, Belmont, MA, 02478, USA.
Psychopharmacology (Berl). 2018 Mar;235(3):789-802. doi: 10.1007/s00213-017-4794-3. Epub 2017 Nov 27.
Nicotine improves attention and processing speed in individuals with schizophrenia. Few studies have investigated the effects of nicotine on cognitive control. Prior functional magnetic resonance imaging (fMRI) research demonstrates blunted activation of dorsal anterior cingulate cortex (dACC) and rostral anterior cingulate cortex (rACC) in response to error and decreased post-error slowing in schizophrenia.
Participants with schizophrenia (n = 13) and healthy controls (n = 12) participated in a randomized, placebo-controlled, crossover study of the effects of transdermal nicotine on cognitive control. For each drug condition, participants underwent fMRI while performing the stop signal task where participants attempt to inhibit prepotent responses to "go (motor activation)" signals when an occasional "stop (motor inhibition)" signal appears. Error processing was evaluated by comparing "stop error" trials (failed response inhibition) to "go" trials. Resting-state fMRI data were collected prior to the task.
Participants with schizophrenia had increased nicotine-induced activation of right caudate in response to errors compared to controls (DRUG × GROUP effect: p < 0.05). Both groups had significant nicotine-induced activation of dACC and rACC in response to errors. Using right caudate activation to errors as a seed for resting-state functional connectivity analysis, relative to controls, participants with schizophrenia had significantly decreased connectivity between the right caudate and dACC/bilateral dorsolateral prefrontal cortices.
In sum, we replicated prior findings of decreased post-error slowing in schizophrenia and found that nicotine was associated with more adaptive (i.e., increased) post-error reaction time (RT). This proof-of-concept pilot study suggests a role for nicotinic agents in targeting cognitive control deficits in schizophrenia.
尼古丁可改善精神分裂症患者的注意力和处理速度。很少有研究调查尼古丁对认知控制的影响。先前的功能磁共振成像(fMRI)研究表明,精神分裂症患者在做出错误反应时,背侧前扣带皮层(dACC)和前扣带皮层腹侧部(rACC)的激活减弱,以及错误后减速减少。
13 名精神分裂症患者和 12 名健康对照者参加了一项随机、安慰剂对照、交叉研究,以评估透皮尼古丁对认知控制的影响。在每种药物条件下,参与者在执行停止信号任务时接受 fMRI 检查,在该任务中,当偶尔出现“停止(运动抑制)”信号时,参与者试图抑制对“去(运动激活)”信号的优势反应。通过比较“停止错误”试验(反应抑制失败)和“去”试验来评估错误处理。在任务之前采集静息态 fMRI 数据。
与对照组相比,精神分裂症患者在错误反应时右尾状核的尼古丁诱导激活增加(药物×组效应:p < 0.05)。两组在错误反应时均出现 dACC 和 rACC 的显著尼古丁诱导激活。使用错误时的右尾状核激活作为静息态功能连接分析的种子,与对照组相比,精神分裂症患者的右尾状核与 dACC/双侧背外侧前额叶皮质之间的连接明显减少。
总之,我们复制了先前关于精神分裂症患者错误后减速减少的发现,并发现尼古丁与更适应性(即增加)的错误后反应时间(RT)相关。这项概念验证性初步研究表明,尼古丁类药物在治疗精神分裂症认知控制缺陷方面具有一定作用。